Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer
Authors: Yu James B. , Sun Yilun , Jia Angela Y. , Vince Randy A. , Shoag Jonathan E. , Zaorsky Nicholas G. , Spratt Daniel E. 
Published: October 2023

Importance

Randomized clinical trials have demonstrated the noninferiority of shorter radiotherapy (RT) courses (termed hypofractionation) compared with longer RT courses in patients with localized prostate cancer. Although shorter courses are associated with cost-effectiveness, convenience, and expanded RT access, their adoption remains variable.

Objective

To identify the current practice patterns of external beam RT for prostate cancer in the US.

Design, Setting, and Participants

This cohort study obtained data from the National Cancer Database, which collects hospital registry data from more than 1500 accredited US facilities on approximately 72% of US patients with cancer. Patients were included in the sample if they had localized prostate adenocarcinoma that was diagnosed between 2004 and 2020 and underwent external beam RT with curative intent. Analyses were conducted between February and March 2023.

Exposures

Radiotherapy schedules, which were categorized as ultrahypofractionation (≤7 fractions), moderate hypofractionation (20-30 fractions), and conventional fractionation (31-50 fractions).

Main Outcomes and Measures

Longitudinal pattern in RT fractionation schedule was the primary outcome. Multivariable logistic regression was performed to evaluate the variables associated with shorter RT courses. Covariables included age, National Comprehensive Cancer Network risk group, rurality, race, facility location, facility type, median income, insurance type or status, and Charlson-Deyo Comorbidity Index.

Results

A total of 313 062 patients with localized prostate cancer (mean [SD] age, 68.8 [7.7] years) were included in the analysis. There was a temporal pattern of decline in the proportion of patients who received conventional fractionation, from 76.0% in 2004 to 36.6% in 2020 (P for trend &amp;lt;.001). From 2004 to 2020, use of moderate hypofractionation increased from 22.0% to 45.0% (P for trend &amp;lt;.001), and use of ultrahypofractionation increased from 2.0% to 18.3% (P for trend &amp;lt;.001). By 2020, the most common RT schedule was ultrahypofractionation for patients in the low-risk group and moderate hypofractionation for patients in the intermediate-risk group. On multivariable analysis, treatment at a community cancer program (compared with academic or research program; odds ratio [OR], 0.54 [95% CI, 0.52-0.56]; P &amp;lt; .001), Medicaid insurance (compared with Medicare; OR, 1.49 [95% CI, 1.41-1.57]; P &amp;lt; .001), Black race (compared with White race; OR, 0.90 [95% CI, 0.87-0.92]; P &amp;lt; .001), and higher median income (compared with lower median income; OR, 1.28 [95% CI, 1.25-1.31]; P &amp;lt; .001) were associated with receipt of shorter courses of RT.

Conclusions and Relevance

Results of this cohort study showed an increase in the use of shorter courses of RT for prostate cancer from 2004 to 2020; a number of social determinants of health appeared to be associated with reduced adoption of shorter treatment courses. Realignment of reimbursement models may be necessary to enable broader adoption of ultrahypofractionation to support technology acquisition costs.